This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Earnings Season Could Be Great for Aldeyra Therapeutics (ALDX)
by Radhika Saraogi
Aldeyra Therapeutics (ALDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
Vaxart (VXRT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Vaxart's (VXRT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its oral COVID-19 vaccine candidate, VXA-CoV2-1.
Has Aldeyra Therapeutics (ALDX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALDX) Outperforming Other Medical Stocks This Year?
4 Small Drug Stocks to Look Out For Amid Coronavirus Uncertainty
by Kinjel Shah
There is uncertainty about the impact of the coronavirus pandemic on the Zacks Medical-Drugs industry. However, with demand trends expected to improve in the second half of 2020, SAVA, KMPH, NERV, ALDX may prove to be good additions to the portfolio.
Heron's (HRTX) Pain Drug Zynrelef Gets EU Approval, Shares Up
by Zacks Equity Research
Heron's (HRTX) Zynrelef gains a marketing nod from the European Commission for managing postoperative pain in surgical wounds among adult patients. Stock rises.
Pacira (PCRX) Gains Positive CHMP Opinion for Exparel in EU
by Zacks Equity Research
The CHMP gives a positive opinion recommending an approval for Pacira's (PCRX) Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALDX) Outperforming Other Medical Stocks This Year?
Savara to Stop Study on Molgradex for NTM Lung Infection
by Zacks Equity Research
Savara (SVRA) to halt the ENCORE study on its lead candidate Molgradex, which was meant to treat nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis.
Zacks.com featured highlights include: Fulgent Genetics, Primoris Services, Niu Technologies, Surface Oncology and Aldeyra Therapeutics
by Zacks Equity Research
Zacks.com featured highlights include: Fulgent Genetics, Primoris Services, Niu Technologies, Surface Oncology and Aldeyra Therapeutics
5 Stocks to Buy as Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Has Aldeyra Therapeutics (ALDX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALDX) Outperforming Other Medical Stocks This Year?
5 Stocks to Snap Up on Coverage Initiation by Analysts
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Aldeyra Therapeutics, Inc. (ALDX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Aldeyra Therapeutics, Inc. (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aldeyra's (ALDX) Q2 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Aldeyra (ALDX) reports narrower-than-expected loss in the second quarter of 2020.
Aldeyra (ALDX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Aldeyra's (ALDX) pipeline progress will be in focus when it reports Q2 results later in the week.
Zynerba's Zygel Fails in Phase III Fragile X Syndrome Study
by Zacks Equity Research
Zynerba's (ZYNE) shares plunge 48.5% following the study data readout, which demonstrated failure to achieve statistical significance in primary endpoint.
Alpine Begins Dosing in Phase I Study for Advanced Malignancies
by Zacks Equity Research
Alpine (ALPN) doses the first patient in the phase I NEON-1 study evaluating its pipeline candidate ALPN-202 for treating patients with advanced malignancies.
What Makes Aldeyra Therapeutics, Inc. (ALDX) a New Strong Buy Stock
by Zacks Equity Research
Aldeyra Therapeutics, Inc. (ALDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aclaris Gets FDA Nod to Start Investigator-led Coronavirus Study
by Zacks Equity Research
Aclaris (ACRS) announces that it supports an IND application to evaluate its oral investigational MK2 inhibitor compound, ATI-450, in hospitalized patients with COVID-19.
FibroGen (FGEN) in Focus: Stock Moves 6.5% Higher
by Zacks Equity Research
FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Ironwood Pharmaceuticals (IRWD) Looks Good: Stock Adds 7.6% in Session
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Cassava Sciences (SAVA) in Focus: Stock Moves 8.5% Higher
by Zacks Equity Research
Cassava Sciences (SAVA) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
How Aldeyra (ALDX) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Aldeyra (ALDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Momentum Stocks to Buy for May 14th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 14th